Organoidsciences Ltd
Company Profile
Business description
Organoidsciences Ltd is a biotechnology company specializing in organoid technology, developing regenerative therapeutics and drug discovery solutions based on three-dimensional organoids. Its business includes ATORM, an organoid-based regenerative therapeutics pipeline, and ODISEI, an organoid-based drug discovery platform. ATORM is a regenerative therapeutic pipeline leveraging organoids derived from various human tissues, including the intestine and salivary gland, to develop novel treatments for a wide range of diseases. ODISEI is an organoid-based drug discovery solution that utilizes disease-specific organoids-including tumor, viral infection, intestinal, and skin organoids-to predict and evaluate human biological responses.
Contact
338 Pangyo-ro
6th floor, Bundang-gu
Gyeonggi-do
Seongnam-si
KORT: +82 27072024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
86
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
stocks
The World Cup stock you’ve never heard of
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,994.60 | 1.80 | -0.02% |
| CAC 40 | 8,338.97 | 12.35 | 0.15% |
| DAX 40 | 25,067.09 | 51.18 | -0.20% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,497.29 | 24.84 | 0.24% |
| HKSE | 24,175.12 | 144.94 | 0.60% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 68,892.31 | 334.59 | 0.49% |
| NZX 50 Index | 13,731.50 | 54.17 | -0.39% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,796.10 | 0.70 | -0.01% |
| SSE Composite Index | 3,996.16 | 40.43 | -1.00% |